The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study

The effect of mirabegron, used for overactive bladder treatment, on female sexual function: a prospective controlled study

Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function. Eighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC urology 2018-06, Vol.18 (1), p.61-8, Article 61
Hauptverfasser: Zachariou, A, Mamoulakis, C, Filiponi, M, Dimitriadis, F, Giannakis, J, Skouros, S, Tsounapi, P, Takenaka, A, Sofikitis, N
Format: Artikel
Sprache:eng
Schlagworte:
Acetanilides - pharmacology
Acetanilides - therapeutic use
Adrenergic beta-3 Receptor Agonists - pharmacology
Adrenergic beta-3 Receptor Agonists - therapeutic use
Adult
Arousal
Bladder
Care and treatment
Female
Female sexual dysfunction
Females
Humans
Kinases
Middle Aged
Mirabegron
Orgasm - drug effects
Orgasm - physiology
Overactive bladder
Pain
Patients
Prospective Studies
Sexual Health
Smooth muscle
Statistical analysis
Studies
Thiazoles - pharmacology
Thiazoles - therapeutic use
Treatment Outcome
Urinary Bladder, Overactive - drug therapy
Urinary Bladder, Overactive - physiopathology
Urinary incontinence
Urological Agents - pharmacology
Urological Agents - therapeutic use
Urology
Womens health
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Αim of the study was to determine the effect of mirabegron, used for overactive bladder (OAB) treatment, on female sexual function. Eighty five sexually active women suffering from overactive bladder were prospectively enrolled in this study. Females were divided into two groups. In Group A (control), 48 patients received no treatment and in Group B, 37 patients received mirabegron 50 mg/daily for 3 months. Patients were evaluated with FSFI-Gr at the beginning of the study and again after a period of 3 months. In Group B, there was a significant increase post-treatment compared to baseline (p 
ISSN:1471-2490
1471-2490
DOI:10.1186/s12894-018-0377-9